Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum...

Area of Science:

• Immunology
• Molecular Biology
• Pulmonary Medicine

Background:

• p38 mitogen-activated protein kinase (MAPK) signaling pathway is activated by various stimuli and implicated in chronic obstructive pulmonary disease (COPD).
• Increased p38 MAPK activation in COPD lungs and reduced systemic inflammation biomarkers (CRP, fibrinogen) with p38 MAPK inhibitors in clinical trials.
• CRP and fibrinogen are linked to adverse clinical outcomes in COPD patients, including mortality and hospitalization.

Purpose of the Study:

• To investigate the impact of p38 MAPK inhibition on the inflammatory gene expression in immune cells of COPD patients.
• To understand the molecular mechanisms by which p38 MAPK inhibition affects systemic inflammation markers like CRP and fibrinogen.

Main Methods:

• Analysis of gene expression data from whole blood and induced sputum samples of COPD subjects treated with dilmapimod.
• Utilized gene array and PCR to measure mRNA levels.
• Employed pathway and network analysis to identify regulated genes.

Main Results:

• Dilmapimod regulated genes including STAT1, MMP-9, CAV1, and IL-1β, which could influence fibrinogen levels.
• IL-1β was identified as a gene regulated by dilmapimod that could also influence C-reactive protein (CRP) levels.
• Demonstrated differential effects of p38 MAPK inhibition on CRP and fibrinogen levels.

Conclusions:

• p38 MAPK inhibition by dilmapimod modulates specific inflammatory pathways in COPD patients.
• The findings suggest distinct molecular mechanisms underlying the effects of p38 MAPK inhibition on CRP and fibrinogen.
• This research provides insights into the targeted anti-inflammatory potential of p38 MAPK inhibitors in COPD management.